- Presentation to Be Webcast Live on Company's Website -

TUSTIN, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company developing targeted therapeutics for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that senior management will present at the BIO CEO & Investor Conference 2007 on Wednesday, February 14, 2007 at 12:00 pm EST. The conference will be held at the Waldorf Astoria Hotel in New York City.

Peregrine CEO and president Steven W. King will provide a review of recent corporate developments.

Mr. King's presentation will be webcast live and can be accessed by visiting the Investor Relations section of Peregrine's website at www.peregrineinc.com. A replay will be available on the Peregrine website and archived for approximately 30 days.

    For more information about this conference, please visit:
    http://ceo.bio.org/opencms/ceo/2007/index.jsp



    About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing five separate clinical trials in cancer and HCV infection with its lead product candidates bavituximab and Cotara® in the U.S. and India. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                         Media
    info@peregrineinc.com                             Barbara Lindheim
    (800) 987-8256                                    (212) 918-4650





SOURCE  Peregrine Pharmaceuticals, Inc.
    -0-                             02/07/2007
    /CONTACT:  Investors, +1-800-987-8256, info@peregrineinc.com, or Media,
Barbara Lindheim, +1-212-918-4650, both of GendeLLindheim BioCom Partners, for
Peregrine Pharmaceuticals, Inc./
    /Web site:  http://ceo.bio.org/opencms/ceo/2007/index.jsp /
    /Web site:  http://www.peregrineinc.com /
    (PPHM)



CO:  Peregrine Pharmaceuticals, Inc.
ST:  California, New York
IN:  HEA MTC BIO FIN
SU:  TDS



LP
-- LAW059 --
1741 02/07/2007 07:00 EST http://www.prnewswire.com